GSK terminates collaboration with Alector after Phase 3/2 failures; loan repaid

Alector, Inc.

GSK provided notice terminating the collaboration agreement for latozinemab and nivisnebart, effective Jan 2, 2027.
Phase 3 INFRONT-3 trial of latozinemab in FTD-GRN missed co-primary endpoint (Oct 2025); Phase 2 PROGRESS-AD of nivisnebart discontinued (Apr 2026).
Alector repaid $10.4M principal plus interest and fees to Hercules Capital, terminating the loan agreement on July 8, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.